Development of a UPLC-MS/MS method for the determination of sulfatinib and its no interaction with myricetin in rats
IntroductionSulfatinib is a novel oral tyrosine kinase inhibitor (TKI) with selective inhibition of fibroblast growth factor (FGFR), colony-stimulating factor 1 receptor (CSF-1R) and vascular endothelial growth factor receptor (VEGFR) 1, 2, and 3. It has been approved for the therapy of neuroendocri...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1498339/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846141349829541888 |
|---|---|
| author | Dongxin Chen Jie Chen Hailun Xia Xiaohai Chen Jinyu Hu Guangliang Wu Xuegu Xu |
| author_facet | Dongxin Chen Jie Chen Hailun Xia Xiaohai Chen Jinyu Hu Guangliang Wu Xuegu Xu |
| author_sort | Dongxin Chen |
| collection | DOAJ |
| description | IntroductionSulfatinib is a novel oral tyrosine kinase inhibitor (TKI) with selective inhibition of fibroblast growth factor (FGFR), colony-stimulating factor 1 receptor (CSF-1R) and vascular endothelial growth factor receptor (VEGFR) 1, 2, and 3. It has been approved for the therapy of neuroendocrine tumors arising in the non-pancreatic (December 2020) and pancreatic (June 2021) glands. Until now, there has no research on the determination of sulfatinib in biological medium by ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method.MethodsThe current study validated a sensitive and reliable quantitative detection of sulfatinib in plasma using UPLC-MS/MS for the first time, and investigated the interaction with myricetin in rats. Acetonitrile was used to precipitate the plasma protein, and lenvatinib was employed as the internal standard (IS).ResultsThe method demonstrated that sulfatinib presented high linearity over the concentration of 11–2,000 ng/mL with the lower limit of quantification (LLOQ) of 1 ng/mL. It was validated methodologically that the precision, matrix effect, stability, accuracy and extraction recovery were all within the allowable values. Moreover, male Sprague-Dawley (SD) rats were assigned randomly to assess the interaction between sulfatinib (30 mg/kg) and myricetin (50 mg/kg). Nevertheless, no significant differences of the main pharmacokinetic parameters were revealed. This may be due to insufficient doses of myricetin, or failure of myricetin to act in a timely manner in vivo.DiscussionThe findings contributed to a better understanding of the metabolism and drug-drug interaction of sulfatinib, but the presence or absence of interactions needs to be confirmed by further studies. |
| format | Article |
| id | doaj-art-5ea0dc0c17c64a22893332fdae6ae45f |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-5ea0dc0c17c64a22893332fdae6ae45f2024-12-04T11:40:24ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122024-12-011510.3389/fphar.2024.14983391498339Development of a UPLC-MS/MS method for the determination of sulfatinib and its no interaction with myricetin in ratsDongxin Chen0Jie Chen1Hailun Xia2Xiaohai Chen3Jinyu Hu4Guangliang Wu5Xuegu Xu6The Affiliated Lihuili Hospital, Ningbo University, Ningbo, Zhejiang, ChinaThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, ChinaThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, ChinaThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, ChinaThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, ChinaThe Affiliated Lihuili Hospital, Ningbo University, Ningbo, Zhejiang, ChinaThe Eye Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, ChinaIntroductionSulfatinib is a novel oral tyrosine kinase inhibitor (TKI) with selective inhibition of fibroblast growth factor (FGFR), colony-stimulating factor 1 receptor (CSF-1R) and vascular endothelial growth factor receptor (VEGFR) 1, 2, and 3. It has been approved for the therapy of neuroendocrine tumors arising in the non-pancreatic (December 2020) and pancreatic (June 2021) glands. Until now, there has no research on the determination of sulfatinib in biological medium by ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method.MethodsThe current study validated a sensitive and reliable quantitative detection of sulfatinib in plasma using UPLC-MS/MS for the first time, and investigated the interaction with myricetin in rats. Acetonitrile was used to precipitate the plasma protein, and lenvatinib was employed as the internal standard (IS).ResultsThe method demonstrated that sulfatinib presented high linearity over the concentration of 11–2,000 ng/mL with the lower limit of quantification (LLOQ) of 1 ng/mL. It was validated methodologically that the precision, matrix effect, stability, accuracy and extraction recovery were all within the allowable values. Moreover, male Sprague-Dawley (SD) rats were assigned randomly to assess the interaction between sulfatinib (30 mg/kg) and myricetin (50 mg/kg). Nevertheless, no significant differences of the main pharmacokinetic parameters were revealed. This may be due to insufficient doses of myricetin, or failure of myricetin to act in a timely manner in vivo.DiscussionThe findings contributed to a better understanding of the metabolism and drug-drug interaction of sulfatinib, but the presence or absence of interactions needs to be confirmed by further studies.https://www.frontiersin.org/articles/10.3389/fphar.2024.1498339/fullsulfatinibmyricetindrug-drug interactionpharmacokineticsUPLC-MS/MS |
| spellingShingle | Dongxin Chen Jie Chen Hailun Xia Xiaohai Chen Jinyu Hu Guangliang Wu Xuegu Xu Development of a UPLC-MS/MS method for the determination of sulfatinib and its no interaction with myricetin in rats Frontiers in Pharmacology sulfatinib myricetin drug-drug interaction pharmacokinetics UPLC-MS/MS |
| title | Development of a UPLC-MS/MS method for the determination of sulfatinib and its no interaction with myricetin in rats |
| title_full | Development of a UPLC-MS/MS method for the determination of sulfatinib and its no interaction with myricetin in rats |
| title_fullStr | Development of a UPLC-MS/MS method for the determination of sulfatinib and its no interaction with myricetin in rats |
| title_full_unstemmed | Development of a UPLC-MS/MS method for the determination of sulfatinib and its no interaction with myricetin in rats |
| title_short | Development of a UPLC-MS/MS method for the determination of sulfatinib and its no interaction with myricetin in rats |
| title_sort | development of a uplc ms ms method for the determination of sulfatinib and its no interaction with myricetin in rats |
| topic | sulfatinib myricetin drug-drug interaction pharmacokinetics UPLC-MS/MS |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2024.1498339/full |
| work_keys_str_mv | AT dongxinchen developmentofauplcmsmsmethodforthedeterminationofsulfatinibanditsnointeractionwithmyricetininrats AT jiechen developmentofauplcmsmsmethodforthedeterminationofsulfatinibanditsnointeractionwithmyricetininrats AT hailunxia developmentofauplcmsmsmethodforthedeterminationofsulfatinibanditsnointeractionwithmyricetininrats AT xiaohaichen developmentofauplcmsmsmethodforthedeterminationofsulfatinibanditsnointeractionwithmyricetininrats AT jinyuhu developmentofauplcmsmsmethodforthedeterminationofsulfatinibanditsnointeractionwithmyricetininrats AT guangliangwu developmentofauplcmsmsmethodforthedeterminationofsulfatinibanditsnointeractionwithmyricetininrats AT xueguxu developmentofauplcmsmsmethodforthedeterminationofsulfatinibanditsnointeractionwithmyricetininrats |